NEW DELHI, India, Dec. 3 /PRNewswire-Asia/ -- Dr. Susan Jiang, M.D., Ph.D., Chief Science Officer at Shenzhen Beike Biotechnology Co. Ltd. (http://www.beikebiotech.com ), spoke at a conference on High-Risk Diabetic Foot Care in New Delhi, India, November 22, 2009. Beike is China's leading stem cell research and regenerative medicine company.
The conference, organized by the Indian Podiatry Association (IPA), aimed to help podiatrists and researchers with an interest in foot disease to "update, interact, modernize and catch up with the advancing pace of scientific development in the field of podiatry." Dr. Jiang's talk, titled "Umbilical Cord Mesenchymal Stem Cell and Clinical Application Prospects in Diabetic Foot Disease," outlined the promise of stem cells in the healing of diabetic wounds and diabetic foot pathology.
"I am excited to have had this opportunity to discuss the role that stem cell therapy can play in healing diabetic wounds and related foot conditions," said Dr. Susan Jiang, speaking after the Conference. "India is one of the first countries to put forth clear and practical guidelines on the clinical use of stem cells. It has also been at the forefront in embracing this new technology, and utilizing its potential clinical applications. Together with leading clinicians in the field, Beike India is preparing a clinical trial of stem cell treatment in diabetic foot disease. Our pilot studies in China suggest that stem cell treatment will become a very practical and effective clinical intervention. We are happy to share our observations from our stem cell therapy studies with the Indian clinical community."
Dr. Jiang's presentation highlighted the results and techniques used in
Beike's Diabetic Foot clinical study performed in China. In December 2008,
Beike completed a prospective clinical study scientifically testing the
|SOURCE Beike Biotech Company Limited|
Copyright©2009 PR Newswire.
All rights reserved